ReVision
Optics, Inc. (RVO), a leader in implantable inlay technology to
treat presbyopia, announces the advancement of its proprietary product
PresbyLens
into the final phase of its U.S. clinical trial under an Investigational
Device Exemption (IDE). PresbyLens is a clear, circular corneal inlay
comprised of approximately 80% water and is less than half the thickness
of a human hair. The Phase 3 clinical trial will evaluate the safety and effectiveness of
the PresbyLens in improving near vision in subjects with presbyopia. In
this prospective, multi-center trial, subjects will be implanted with the
PresbyLens in their non-dominant eye.
Read more.
No comments:
Post a Comment